ImmunityBio, Inc.
Status: Publicly traded
Direct answer
ImmunityBio, Inc. is publicly traded on NASDAQ under the ticker IBRX.
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion...
Can you invest in ImmunityBio, Inc.?
Yes. ImmunityBio, Inc. trades publicly on NASDAQ as IBRX.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for ImmunityBio, Inc.
Detailed equity research is provided by MarketSnap.